V. Cooke

发表

Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia

Jacob D. Jaffe, J. Downing, S. Carr, 2013, Nature Genetics.

JAM-A is present in mammalian spermatozoa where it is essential for normal motility.

P. Martin-DeLeon, U. Naik, Ananya Ghosh, 2008, Developmental biology.

Studying clonal dynamics in response to cancer therapy using high-complexity barcoding

Joshua M. Korn, Franziska Michor, Derek Y. Chiang, 2015, Nature Medicine.

Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases

Ping Zhu, Gang Liu, Peter Fekkes, 2016, Nature.

VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization

Raghu Kalluri, Rajan Dewar, Hikaru Sugimoto, 2011, Proceedings of the National Academy of Sciences.

Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity

R. Kalluri, M. Kieran, Y. Maeshima, 2008, Proceedings of the National Academy of Sciences.

Origin and function of myofibroblasts in kidney fibrosis

R. Kalluri, C. Woda, Joyce T. O’Connell, 2013, Nature Medicine.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Donna Neuberg, Steven M Kornblau, Johannes Köster, 2016, Cancer cell.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Donna Neuberg, Steven M Kornblau, Johannes Köster, 2016, Cancer cell.

An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).

Joshua M. Korn, Ping Zhu, Sunkyu Kim, 2013, Cancer discovery.

Targeting vascular pericytes in hypoxic tumors increases lung metastasis via angiopoietin-2.

R. Kalluri, Chia-Chin Wu, Michele De Palma, 2015, Cell reports.

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097

M. Wiesmann, J. Griffin, Irene Simkin, 2015, Molecular Cancer Therapeutics.

Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma

Joshua M. Korn, Tara L. Naylor, Michael P. Morrissey, 2013, Nature Medicine.

Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway.

Zainab N. Khan, R. Kalluri, R. Brentani, 2012, Cancer cell.

Fibroblast Growth Factor-2 Failed to Induce Angiogenesis in Junctional Adhesion Molecule-A–Deficient Mice

U. Naik, M. Naik, V. Cooke, 2006, Arteriosclerosis, thrombosis, and vascular biology.

An F 876 L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV 3100 ( Enzalutamide )

Joshua M. Korn, W. Sellers, J. Korn, 2013 .

Chapter 1. Molecular mechanism of type IV collagen-derived endogenous inhibitors of angiogenesis.

R. Kalluri, V. Cooke, 2008, Methods in enzymology.

LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors

P. Hammerman, G. Caponigro, F. Mapa, 2020, Clinical Cancer Research.

Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic.

W. Sellers, M. P. Dillon, Y. Mishina, 2020, Journal of medicinal chemistry.

VEGF-A and Tenascin-C produced by S100A4[superscript +] stromal cells are important for metastatic colonization

R. Kalluri, R. Brentani, R. Rocha, 2011 .

Deletion of JAM-A causes morphological defects in the corneal epithelium.

K. Czymmek, M. Duncan, Yan Wang, 2007, The international journal of biochemistry & cell biology.

JAM‐A expression during embryonic development

W. Skarnes, Vesselina G. Cooke, M. Duncan, 2005, Developmental dynamics : an official publication of the American Association of Anatomists.

Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers.

M. P. Dillon, Mallika Singh, E. Lees, 2017, Journal of medicinal chemistry.

Inhibiting Tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling.

Dmitriy Sonkin, Joshua M. Korn, William R Sellers, 2014, Cancer research.

Therapeutics , Targets , and Chemical Biology Inhibiting Tankyrases Sensitizes KRAS-Mutant Cancer Cells to MEK Inhibitors via FGFR 2 Feedback Signaling

Joshua M. Korn, W. Sellers, J. Korn, 2014 .

Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.

Joshua M. Korn, W. Sellers, F. Shen, 2018, Cancer research.

Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study

D. Schadendorf, C. Dooms, P. Ascierto, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

M. P. Dillon, Mallika Singh, E. Lees, 2017, Journal of medicinal chemistry.